Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS2P55 is a processed pseudogene of the ribosomal protein S2 gene (RPS2) in Homo sapiens. Like other ribosomal protein pseudogenes, it likely arose through retrotransposition of mRNA from the parental RPS2 gene back into the genome without subsequent functionalization or maintenance of protein-coding capacity[1][2][3]. RPS2P55 does not produce a functional protein and is not considered a therapeutic or functional molecular target. Pseudogenes of ribosomal proteins are widespread in the human genome and are generally regarded as relics of genome evolution, though a minority of pseudogenes in some families may retain rare regulatory functions. There is no evidence in the available literature that RPS2P55 has any specific biological, disease, or therapeutic relevance. Key points: - The canonical, full functional gene in this family encodes a ribosomal protein (see RPS2), but RPS2P55 itself is a nonfunctional genomic remnant. - RPS2P55 should not be confused with RPS2, which is part of the ribosome responsible for translation in the cytoplasm[4][7]. - No clinical, experimental, or pharmacological interventions are known to target RPS2P55[2][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S2 pseudogene 55 (RPS2P55).